Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

11.13 +0.36 (+3.29%)

Delayed Quote Updated: 3:49 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Churchill Capital Corp XI - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

The First Pure-Play Humanoid Robot Stock Is About to Go Public. Here's What Investors Need to Know About Agility Robotics. ↗

Today 10:35 EDT

Like many other up-and-coming companies that are going public specifically because their business and their industry are clearly at a turning point, there's plenty of price-inflating hope here.

Via The Motley Fool

Topics Artificial Intelligence Electric Vehicles

Agility Robotics to Livestream Analyst & Investor Day Today

October 06, 2026

From Agility Robotics

Via Business Wire

Agility Robotics Announces New Directors for Planned Public-Company Board

September 29, 2026

From Agility Robotics

Via Business Wire

Agility to Host Analyst & Investor Day on October 6, 2026

September 17, 2026

From Agility Robotics

Via Business Wire

Agility Robotics to Attend Upcoming Investor Conferences

August 27, 2026

From Agility Robotics

Via Business Wire

Agility Robotics and Churchill Capital Corp XI Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination

July 14, 2026

From Agility Robotics, Inc.

Via Business Wire

Grounded: SpaceX Stumbles as Grok Fails to Ignite ↗

July 09, 2026

SpaceX shares fell 8% after Nasdaq 100 inclusion as Grok's market share slipped, while Tesla dropped 7% despite a delivery beat, reflecting fading AI-driven valuation premiums.

Via MarketBeat

Topics Artificial Intelligence

Unusual volume stocks are being observed in Monday's session. ↗

July 06, 2026

Via Chartmill

Unusual volume stocks in Thursday's session ↗

July 02, 2026

Via Chartmill

Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI ↗

July 02, 2026

The CCXI-Agility Robotics SPAC merger will create the first U.S.-listed pure-play humanoid equity, valued at $2.5B, with clients including Amazon and a NVIDIA partnership.

Via MarketBeat

Topics Artificial Intelligence ETFs

On Wednesday, there are stocks with unusual volume. Let's take a look. ↗

July 01, 2026

Via Chartmill

The trading volume of these stocks is deviating from the norm in today's session. ↗

June 30, 2026

Via Chartmill

The trading volume of these stocks is deviating from the norm in today's session. ↗

June 29, 2026

Via Chartmill

The trading volume of these stocks is deviating from the norm in today's session. ↗

June 26, 2026

Via Chartmill

These stocks have an unusual volume in today's session ↗

June 25, 2026

Via Chartmill

Agility Robotics to Go Public Through $2.5 Billion Merger with Churchill Capital Corp XI

June 24, 2026

From Agility Robotics, Inc.

Via Business Wire

Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share ↗

December 12, 2022

Via Benzinga

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

October 17, 2022

From ChemoCentryx, Inc.

Via GlobeNewswire

Biotech Stocks Well-Positioned For The Fourth Quarter ↗

October 12, 2022

The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.

Via Talk Markets

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 05, 2022

From ChemoCentryx, Inc.

Via GlobeNewswire

These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022 ↗

September 20, 2022

We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022.

Via Talk Markets

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year ↗

September 19, 2022

The biotech run off a June bottom is great — until you realize you could've netted more.

Via Investor's Business Daily

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI

September 13, 2022

From Scott+Scott Attorneys at Law LLP

Via Business Wire

7 Dow Stocks With Superior Fundamentals ↗

September 06, 2022

Robust Dow stocks offer attractive deals for patient investors amidst an unstable economic environment

Via InvestorPlace

Healthcare Sector Still Looks Good But Lacks Momentum ↗

September 06, 2022

The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord...

Via Talk Markets

ChemoCentryx's Return On Capital Employed Insights ↗

September 01, 2022

According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million.

Via Benzinga

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI

August 30, 2022

From Scott+Scott Attorneys at Law LLP

Via Business Wire

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.